CinCor Pharma Inc (CINC)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Marc M. P. de Garidel
Employees:
20
200 CLARENDON STREET, 6TH FLOOR, BOSTON, MA 02116
8445311834

CinCor Pharma, Inc. engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteroni® and others. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Data derived from most recent annual or quarterly report
Market Cap 1.272 Billion Shares Outstanding43.764 Million Avg 30-day Volume 714.238 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.56
Price to Revenue0.0 Debt to Equity0.0 EBITDA-76.485 Million
Price to Book Value2.4042 Operating Margin0.0 Enterprise Value416.697 Million
Current Ratio41.607 EPS Growth0 Quick Ratio40.417
1 Yr BETA 0.7197 52-week High/Low 43.15 / 10.53 Profit Margin0.0
Operating Cash Flow Growth0.0 Free Cash Flow to Firm (FCFF) TTM 0 Free Cash Flow to Equity (FCFE) TTM-47.586 Million
Altman Z-Score58.3891
View SEC Filings from CINC instead.

View recent insider trading info

CinCor Pharma Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding CINC (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CINC

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-02-28 by SCHWAB ANDREW J.
  • 4: filed on 2023-02-27 by FREEMAN MASON
  • 4: filed on 2023-02-24 by ALLISON DAVID D.
  • 4: filed on 2023-02-24 by IGNELZI TROY A.
  • 4: filed on 2023-02-24 by KALB MICHAEL WAYNE
  • 4: filed on 2023-02-24 by LEE JUNE
  • 4: filed on 2023-02-24 by PEARCE CATHERINE
  • 4: filed on 2023-02-24 by THERO JOHN F
  • 4: filed on 2023-02-24 by DE GARIDEL MARC
  • 4: filed on 2023-01-19 by PEARCE CATHERINE

    • Events (8k)

  • 8-K: filed on 2023-02-24:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-21:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-09:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-28:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-08:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-07:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K/A: filed on 2022-11-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-11:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    THERO JOHN F

    • Director
    		 0 2023-02-24 1

    IGNELZI TROY A.

    • Director
    		 0 2023-02-24 1

    5AM PARTNERS VI, LLC

    5AM VENTURES VI, L.P.

    5AM OPPORTUNITIES I, L.P.

    SCHWAB ANDREW J.

    PARMAR KUSH

    5AM OPPORTUNITIES II (GP), LLC

    5AM OPPORTUNITIES II, L.P.

    5AM OPPORTUNITIES I (GP), LLC

    • 10% Owner
    		 0 2023-02-24 1

    KALB MICHAEL WAYNE EVP & CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-02-24 4

    LEE JUNE

    • Director
    		 0 2023-02-24 1

    ALLISON DAVID D.

    • Director
    		 0 2023-02-24 3

    PEARCE CATHERINE CHIEF OPERATING OFFICER

    • Officer
    		 0 2023-02-24 3

    DE GARIDEL MARC CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2023-02-24 2

    FREEMAN MASON CHIEF MEDICAL OFFICER

    • Officer
    		 42,600 2023-01-26 1

    HEALY JAMES

    KATABI MAHA

    SOFINNOVA MANAGEMENT X, L.P.

    SOFINNOVA MANAGEMENT X-A, L.L.C.

    SOFINNOVA VENTURE PARTNERS X, L.P.

    • Director
    • 10% Owner
    		 0 2022-11-28 1

    SOFINNOVA PARTNERS SAS

    SOFINNOVA CAPITAL IX

    • 10% Owner
    		 4,220,979 2022-08-15 0

    GENERAL ATLANTIC, L.P.

    GENERAL ATLANTIC GENPAR, L.P.

    GENERAL ATLANTIC PARTNERS 100, L.P.

    GAP COINVESTMENTS III, LLC

    GAP COINVESTMENTS IV, LLC

    GAP COINVESTMENTS V, LLC

    GENERAL ATLANTIC PARTNERS (BERMUDA) EU, L.P.

    GENERAL ATLANTIC PARTNERS (LUX), SCSP

    GENERAL ATLANTIC (LUX) S.A R.L.

    GENERAL ATLANTIC GENPAR (LUX) SCSP

    • 10% Owner
    		 4,209,470 2022-08-11 0

    HEALY JAMES

    • Director
    • 10% Owner
    		 6,109,360 2022-08-11 1

    GENERAL ATLANTIC GENPAR (BERMUDA), L.P.

    GAP (BERMUDA) L.P.

    GAP COINVESTMENTS CDA, L.P.

    GENERAL ATLANTIC (CIN), L.P.

    GENERAL ATLANTIC (SPV) GP, LLC

    • 10% Owner
    		 4,209,470 2022-08-11 0

    SOFINNOVA VENTURE PARTNERS X, L.P.

    SOFINNOVA MANAGEMENT X, L.L.C.

    KATABI MAHA

    • 10% Owner
    		 6,073,949 2022-08-11 0

    5AM PARTNERS VI, LLC

    5AM VENTURES VI, L.P.

    5AM OPPORTUNITIES I (GP), LLC

    5AM OPPORTUNITIES I, L.P.

    SCHWAB ANDREW J.

    PARMAR KUSH

    • 10% Owner
    		 8,205,292 2022-01-11 1

    COELHO MARY THERESA EVP CFO & CHIEF BD OFFICER

    • Officer
    		 100 2022-01-11 0

    CINRX PHARMA, LLC

    • 10% Owner
    		 3,630,103 2022-01-11 0

    GENERAL ATLANTIC, L.P.

    GAP (BERMUDA) L.P.

    GENERAL ATLANTIC GENPAR (BERMUDA), L.P.

    GENERAL ATLANTIC (LUX) S.A R.L.

    GENERAL ATLANTIC GENPAR (LUX) SCSP

    GENERAL ATLANTIC PARTNERS (LUX), SCSP

    GENERAL ATLANTIC PARTNERS 100, L.P.

    GENERAL ATLANTIC GENPAR, L.P.

    GENERAL ATLANTIC PARTNERS (BERMUDA) EU, L.P.

    GENERAL ATLANTIC (SPV) GP, LLC

    • 10% Owner
    		 0 2022-01-06 0

    GENERAL ATLANTIC (CIN), L.P.

    GAP COINVESTMENTS III, LLC

    GAP COINVESTMENTS IV, LLC

    GAP COINVESTMENTS V, LLC

    GAP COINVESTMENTS CDA, L.P.

    • 10% Owner
    		 0 2022-01-06 0

    PITTS JASON

    • Director
    		 0 2022-01-06 0

    BHAMAN MAINA

    • Director
    		 0 2022-01-06 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CINCOR PHARMA INC CINC 2023-02-24 22:15:04 UTC -0.1128 4.6828 50000
    CINCOR PHARMA INC CINC 2023-02-24 21:45:03 UTC -0.1251 4.6951 50000
    CINCOR PHARMA INC CINC 2023-02-24 21:15:04 UTC -0.1251 4.6951 50000
    CINCOR PHARMA INC CINC 2023-02-24 20:45:03 UTC -0.1251 4.6951 50000
    CINCOR PHARMA INC CINC 2023-02-24 20:15:04 UTC -0.1251 4.6951 50000
    CINCOR PHARMA INC CINC 2023-02-24 19:45:04 UTC -0.1251 4.6951 50000
    CINCOR PHARMA INC CINC 2023-02-24 19:15:03 UTC -0.1251 4.6951 50000
    CINCOR PHARMA INC CINC 2023-02-24 18:45:03 UTC -0.1929 4.7629 50000
    CINCOR PHARMA INC CINC 2023-02-24 18:15:03 UTC -0.1929 4.7629 50000
    CINCOR PHARMA INC CINC 2023-02-24 17:45:03 UTC -0.1929 4.7629 50000
    CINCOR PHARMA INC CINC 2023-02-24 17:15:03 UTC -0.1929 4.7629 100000
    CINCOR PHARMA INC CINC 2023-02-24 16:45:04 UTC -2.7609 7.3309 100000
    CINCOR PHARMA INC CINC 2023-02-24 16:15:03 UTC -2.7609 7.3309 100000
    CINCOR PHARMA INC CINC 2023-02-24 15:45:03 UTC -2.7609 7.3309 150000
    CINCOR PHARMA INC CINC 2023-02-24 15:15:03 UTC -2.7609 7.3309 150000
    CINCOR PHARMA INC CINC 2023-02-24 14:45:03 UTC -2.7609 7.3309 150000
    CINCOR PHARMA INC CINC 2023-02-24 14:15:04 UTC -2.7609 7.3309 150000
    CINCOR PHARMA INC CINC 2023-02-24 13:45:04 UTC -2.7609 7.3309 150000
    CINCOR PHARMA INC CINC 2023-02-24 13:15:04 UTC -2.7609 7.3309 150000
    CINCOR PHARMA INC CINC 2023-02-24 12:45:04 UTC -2.7609 7.3309 150000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments